N°64 - Marché /Nutrition clinique • Pre- and postoperative nutritional solu- logy).This buoyant growth will most likely tions continue given the ageing of the population, In order to help patients prepare for and the increase in the prevalence of chronic recover much faster from surgery, Abbott pathologies and the advances in medical launched in April 2017 two drinks: Ensure® techniques allowing for the detection and Pre Surgery Clear Nutrition, a drink formu- treatment of diseases previously not subject lated with carbohydrates to be drunk 2 hours to reimbursement. The growing transfer prior to surgery in order to help reduce insulin of hospital care towards community care resistance, which increases the risk of infec- also has a mechanical incidence upon such tions and complications, and Ensure Surgery® expenditure. The purpose of the Finance Bill Immunonutrition Shake, a drink rich in argi- for Social Security is to save €100 million nine and omega-3 fatty acids EPA and DHA, on medical devices. which is to be administered after surgery to The announced price lowering has already help with immune health and recovery. These sparked the reactions of the companies in products are designed to be used in hospital this sector and patient associations. In order environments. Nestlé had previously launched to meet these reactions, the Ministry of in 2016 Impact Advance Recovery Drink, a® Social Affairs and Health stated in October drink rich in arginine, an omega-3 fatty acid 2016 that the CEPS had initiated negotia- and in nucleotides to help support the body’s tions with the concerned professional asso- immune response and help reduce the risk ciations. “They allowed reaching a conven- of postoperative infections. The clinical data tional agreement with the representatives shows that when Impact Advanced Reco- of device manufacturers and home care very Drink is consumed for 5 days before® service suppliers. The agreement proposes the surgery, and 5 days after the surgery, the price reductions much below those initially recovery is optimized. At the end of 2017, requested for 2016 and 2017. The agree- 016 Nestlé set up a related website dedicated to ment also includes quantity clauses and patients, www.PreparedForSurgery.com. nomenclature updates,” she said. • Chronic infl ammatory bowel diseases The French market is up again! Chronic infl ammatory bowel diseases are yet another area explored by the players in the Estimated at €281 million in 2013, (The medical nutrition sector. Nestlé proposed at French Association of Clinical Nutrition the end of 2016 the low FODMAP nutritional Companies), the French market for cli- drink ProNourish formulated without gluten® nical nutrition is up again as of 2017 with and lactose, dedicated to patients suffering sales up by 4% amounting to €322 million, from the irritable bowel syndrome. It is the according to the estimates of the Xerfi only drink distributed in the United States research firm. An evaluation below the on this market segment. Nestlé has comple- figures indicated by Nestlé. “In France, mented this product with a “IBCause” Dia- medical nutrition accounts for €360 million gnostic Test developed by Prometeus Lab in with a market whose CAGR is of 2-3% 2017. and was of 2% in 2017,” explains Nestlé Health Science France Marketing Director, France: Reimbursement Carole Bras. The core of this market is rates for clinical nutrition represented by oral nutrition which, accor- products are lowered ding to Carole Bras, accounts for over 70% of the market, that is €260 million: “this In August 2016, the Economic Committee is another highly dynamic market, with for Medicinal Products (CEPS) initiated a a growth rate of +2.5% in 2017.” Finally, procedure aimed at lowering by 4 to 10% allergy products are another fully develo- the prices of certain medical devices, inclu- ping area. “It accounts for €50 million at ding clinical nutrition products, after having a CAGR of 5% in 2017.” noted a signifi cant increase (+5.3% between The strong market growth and favou- 2009-2013) in certain expenditure (home- rable projections for the future are driven use devices, orthopaedics and cardio- by highly structural factors such as the ■ / Juillet - Août - Septembre 2018 / N°64 / L’Actualité des Ingrédients Fonctionnels & Santé